DCEG @ EUROGIN 2024

EUROGIN is the leading International Multidisciplinary HPV Congress, focusing on translating scientific and evidence-based research into clinical practice. Our researchers focus on many different aspects of HPV, from vaccines to clinical screening and management. Notably, this year's conference includes an HPV and Artificial Intelligence Forum. Check out the list below of all the presentations from DCEG scientists.

Wednesday 3/13

Validation of HPV assays

10:30AM-12:00PM CET Auditorium A2

Nicolas Wentzensen: Ranking of HPV genotypes, extended genotyping

Microbiome

1:30- 3:00 PM CET Auditorium A2

Emily Vogtmann : Associations between the oral microbiome and head and neck cancer risk

HPV epidemiology: State of the science to inform cancer prevention

3:30-5PM CET Auditorium A1

Co-Chair: Aimee Kreimer ?

Dr. Kreimer: Single-dose HPV vaccination - from discovery to policy

Jaimie Shing, PhD, MPH : Cervical Precancer – Unmasking in HPV Vaccinated Populations

Cameron B. Haas : Anal cancer, from epidemiology to prevention

Loretto Carvajal: Oropharyngeal Cancer by World Region - Changing Etiologic Fractions

Putting Anal Cancer Screening into Practice: Implementation science, biomarker development, and self-sampling

3:30-5PM CET Room C1/C2

Megan Clarke : What is the current state of biomarker development for anal cancer screening?

Free Communications: Epidemiology I

3:30-5:00PM CET Room C3

Mónica S. Sierra : HPV 16/18 viral clearance and progression to CIN 2+ among women aged 18-25 years enrolled in the Costa Rica HPV Vaccine Trial

How effective is HPV genotyping in screening?

5:00PM-6:30PM CET Auditorium A1

Dr. Wentzensen: The scientific basis of HPV genotyping in screening

?

Thursday 3/14

HPV type replacement

8:00-9:00AM CET Auditorium A1

Dr. Shing: Clinical unmasking of cervical precancers caused by non-vaccine-preventable HPV types following HPV vaccination: A proof-of-concept in the Costa Rica HPV Vaccine Trial

Use of genotyping for management

8:00-9:30AM CET Auditorium A4

Dr. Wentzensen: Rationale of using genotyping for management of cervical cancer

Screening for HPV-related cancer in sexual and gender minority adults

9:30-11:00AM CET Room C3

Co-Chairs:? Sarah Jackson, PhD, MPH and Dr. Kreimer

Dr. Haas: Anal cancer risk and screening strategies in MSM with and without HIV

Dr. Jackson: Cervical cancer screening among trans men and non-binary people in the United Kingdom

HPV and Head & Neck Forum: Epidemiology and prevention of HPV-OPC

2:00-3:30 CET Room C3

Dr. Carvajal: Trends in incidence rates of head and neck squamous cell carcinomas overall and by potential relatedness to human papillomavirus, Costa Rica 2006 to 2015

Rebecca Landy : The potential impact of oropharyngeal cancer screening: results from a natural history simulation model

HPV and Artificial Intelligence Forum: AI and HPV-related neoplasia - Prediction models, experiences and perspectives

2:40-5:15PM CET Auditorium A2

Chair: Dr. Wentzensen

Didem Egemen : Development and evaluation of Automated Visual Evaluation in LMIC

Dr. Wentzensen: Automated detection of dual stain for triage of HPV-positives

?

Friday 3/15

HPV driven cancer among people living with HIV

10:00-11:30 CET Auditorium A2

Meredith Shiels : A global comparison of incidence rates and trends in HPV-related cancers among people with HIV

Dr. Shing: Incidence, trends and burden of HPV-related cancers in a high HIV-setting: the South African National Cancer Registry

Methylation markers as management tool in anal, vulvar and cervical intraepithelial neoplasms

10:00-11:30 CET Auditorium A4

Co-Chair:?Dr. Clarke

Dr. Clarke: Clinical needs of methylation assays in anogenital disease

Scientific Sessions: Debate

2:30-4:00PM ET Auditorium A1

Dr. Wentzensen and Tim Palmer: What is the best endpoint for vaccine efficacy trials?

Global overview of commercial HPV tests: 2024 status

4:00-5:30 CET Room C1/C2

Dr. Wentzensen: Getting new tests into clinical practice: The role of US regulatory and guidelines procedures

?

Saturday 3/16

Risk stratification in cervical cancer screening

8:00-9:30AM CET Room C3

Dr. Egemen: Stratification by extended genotyping and AVE